Precision BioSciences Inc is a biotechnology company that focuses on utilizing its ARCUS genome editing platform to enhance the versatility and efficiency of gene editing. With a strong commitment to next-generation gene therapies, Precision BioSciences aims to address unmet medical needs and transform the lives of patients. The company's corporate philosophy revolves around precision in genome editing, driving innovation in the field of molecular medicine. Precision BioSciences aims to revolutionize the treatment of genetic diseases by delivering safe, effective, and targeted therapies that maximize patient outcomes. With a dedicated team and cutting-edge technology, Precision BioSciences Inc is poised to make significant contributions to the future of genetic medicine.

Precision BioSciences Inc is primarily present in the United States and operates globally. The company's headquarters is located in Durham, North Carolina, USA. Precision BioSciences focuses on developing and commercializing its proprietary ARCUS genome editing platform, which enables precise and efficient gene edits. With a strong presence in the United States, Precision BioSciences also engages in research collaborations and partnerships on a global scale, collaborating with pharmaceutical and biotechnology companies worldwide. The company's commitment to advancing gene editing technologies extends beyond borders, making it a prominent player in the international market.

Precision BioSciences Inc, a leading biotechnology company, has achieved several significant milestones. Notably, the company successfully developed and commercialized its proprietary ARCUS genome editing platform, which offers precise and efficient editing of genes. Precision BioSciences also obtained regulatory approval for multiple clinical trials, showcasing its commitment to advancing innovative therapeutics. Furthermore, the company has fostered collaborations and partnerships with renowned institutions and pharmaceutical companies, expanding its research capabilities and potential market reach. With its cutting-edge technology and strong industry presence, Precision BioSciences Inc continues to make remarkable strides in the field of genome editing and holds immense promise for the future.

Precision BioSciences Inc., a biotechnology company based in Durham, North Carolina, was founded in 2006. The company focuses on developing and commercializing its proprietary genome editing platform called ARCUS. Precision BioSciences utilizes this platform for various applications such as developing transformative gene and cell therapies, creating sustainable food and agriculture solutions, and advancing genetic medicines. The company's ARCUS platform is characterized by its versatility, specificity, and efficacy, enabling precise editing of the genome. Precision BioSciences has established collaborations with renowned organizations to further advance its gene editing capabilities and expand its therapeutic and agricultural product portfolios.

Prominent competitors of Precision BioSciences Inc in the market include but are not limited to Editas Medicine Inc, Intellia Therapeutics Inc, and CRISPR Therapeutics AG.

Precision BioSciences Inc is primarily active in the biotechnology industry.

The business model of Precision BioSciences Inc. revolves around utilizing its proprietary platform called ARCUS to develop gene editing therapies. Precision BioSciences aims to address previously untreatable genetic diseases by using its next-generation genome editing technology. The company focuses on developing and commercializing its gene therapies for various indications to improve patients' lives, having a strong pipeline of therapeutic candidates. Precision BioSciences' business model centers on leveraging its innovative technology to advance precision genome editing solutions and collaborate with partners in the healthcare industry to bring potentially life-changing therapies to patients in need.

Precision BioSciences의 P/E 비율은 -3.59입니다.

Precision BioSciences의 P/S 비율은 0.47입니다.

Precision BioSciences에 대한 AlleAktien 품질 점수는 3/10입니다.

예상되는 Precision BioSciences 매출은 81.18 백만 USD입니다.

예상되는 Precision BioSciences 이익은 -10.64 백만 USD입니다.

Precision BioSciences Inc is a biotechnology company specializing in the development of genetic solutions for healthcare, agriculture, and the energy industry. Founded in 2006, the company is headquartered in Durham, North Carolina. Precision BioSciences' business model is based on the patented ARCUS Genome Editing Technology, which allows for precise and efficient manipulation of genes. The ARCUS platform uses natural proteins called Meganucleases to cut specific DNA sequences in cells. By combining the Meganuclease with an artificial DNA strand, the DNA can be modified at the desired location. The ARCUS technology is applied in various fields to develop innovative solutions. One example is its application in healthcare, where Precision BioSciences develops therapies for rare diseases and cancer. The company works closely with pharmaceutical companies to develop new therapies and conduct clinical trials. Additionally, Precision BioSciences is involved in agriculture, assisting plant breeders in developing plant varieties that are resistant to diseases and extreme weather conditions. The ARCUS technology can also help reduce the use of pesticides and herbicides, thereby protecting the environment. The third sector of Precision BioSciences is the energy industry, where they are working on the development of biofuels. The ARCUS technology can help create new types of biomass that can be used to produce biofuels. Precision BioSciences also offers various products based on the ARCUS technology. These include ARCUS Genome Editing Kits, which provide researchers and scientists with a simple and efficient way to edit genes in a variety of cell types. Additionally, the company offers a proprietary screening system to improve the efficiency and accuracy of gene editing processes. In summary, Precision BioSciences' business model is focused on developing innovative genetic solutions for healthcare, agriculture, and the energy industry. The ARCUS technology provides a precise and effective way to manipulate genes, offering the potential to develop new therapies, plant varieties, and biofuels. The company also offers various products based on the ARCUS technology to improve the efficiency and accuracy of gene editing.

Precision BioSciences은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Precision BioSciences의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Precision BioSciences의 ISIN은 US74019P1084입니다.

Precision BioSciences의 WKN은 A2PGA1입니다.

Precision BioSciences의 티커는 DTIL입니다.

지난 12개월 동안 Precision BioSciences은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Precision BioSciences은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Precision BioSciences의 현재 배당 수익률은 입니다.

Precision BioSciences은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Precision BioSciences은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Precision BioSciences은 '건강' 섹터에 속합니다.

Precision BioSciences의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Precision BioSciences는 0 USD를 배당금으로 지급했습니다.

Precision BioSciences의 배당금은 USD에 지급됩니다.